GARFIELD-AF insights on early mortality, AC treatment in low stroke-risk patients and decline of AP monotherapy, shared at ACC.17
The world’s leading cardiovascular professionals came together in Washington, DC in March for three full days of innovative education, ground-breaking science and interactive debates and discussion.
Professors Samuel Goldhaber, John Camm and Freek Verheugt, members of our Steering Committee, all spoke at ACC.17 to share GARFIELD-AF insights. Below are some highlight quotes from their presentations:
GARFIELD-AF registry speaks on early mortality in patients with newly diagnosed atrial fibrillation (AF)
“There is a clear need for clinicians to provide integrated cardiovascular management to help detect early warning signs of possible early mortality; this is because cardiovascular death and co-morbidities appear to be important components of the early mortality.” – Professor Samuel Goldhaber
Net clinical benefit of anticoagulant (AC) treatment uncertain in guideline-defined low stroke-risk patients
“For guideline-defined low risk stroke patients (i.e. women with a CHA2DS2-VASc score of 2, men with a CHA2DS2-VASc score of 1), risk of stroke was not clearly reduced by AC ± antiplatelet (AP), but was associated with a 3-4 times higher risk of major bleeds.” – Professor John Camm
AP scripts declining but still an important part of stroke prevention strategies in AF
“Antiplatelet monotherapy for stroke prevention is still prescribed in around 10 percent of AF patients eligible for anticoagulants, who do not have vascular disease.” – Professor Freek Verheugt